<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336293</url>
  </required_header>
  <id_info>
    <org_study_id>D3338-P</org_study_id>
    <secondary_id>RX003338</secondary_id>
    <nct_id>NCT04336293</nct_id>
  </id_info>
  <brief_title>sTMS for Substance Use-disordered Veterans</brief_title>
  <official_title>sTMS for Substance Use-disordered Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if synchronized transcranial magnetic stimulation&#xD;
      is safe and tolerable in individuals with cocaine, opioid, or alcohol use disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All non-life-saving human research studies suspended by sponsor in response to COVID19 social&#xD;
      distancing policies&#xD;
&#xD;
      The goal of this proposal is to evaluate preliminary participant response to a pilot,&#xD;
      controlled, feasibility study to evaluate changes in craving, substance use, and quality of&#xD;
      life after 6 weeks of a low-risk non-invasive brain stimulation technique, called&#xD;
      Synchronized Transcranial Magnetic Stimulation (sTMS), compared to sham, in Veterans with a&#xD;
      substance use disorder (SUD). An important focus of this application will be evaluating the&#xD;
      acceptability, tolerability, and safety of sTMS in this population. To the investigators&#xD;
      knowledge, sTMS has never been used for SUDs, and holds considerable promise as a future&#xD;
      treatment option for these prevalent disorders. However initial work in the acceptability,&#xD;
      tolerability, and safety of this approach must be conducted first. This project is the first&#xD;
      step towards the investigators long-term goal, which is to combine non-invasive brain&#xD;
      stimulation with individualized psychotherapy or pharmacotherapy to reduce SUD problems and&#xD;
      improve quality of life for Veterans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind, sham controlled RCT</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quality of Life Enjoyment and Satisfaction Questionnaire&#xD;
The Q-LES-Q-SF evaluates general activities that are assessed in the longer form of the Q- LES-Q. Each item uses a 5-point scale ranging from 1 (very poor) to 5 (very good). A total score is derived from 14 items with a maximum score of 70 and with higher scores indicating greater life satisfaction and enjoyment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>substance specific craving</measure>
    <time_frame>6 weeks</time_frame>
    <description>self reported reactivity to associated cues with 8 items ranked 1-7--higher scores indicating greater craving/urges</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Social and Occupational Functioning Assessment Scale (SOFAS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The SOFAS is a global rating of current functioning ranging from 0 to 100, with lower scores representing lower functioning.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cocaine Addiction</condition>
  <condition>Opioid Addiction</condition>
  <condition>Alcohol Addiction</condition>
  <arm_group>
    <arm_group_label>active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active sTMS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham sTMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sTMS</intervention_name>
    <description>sTMS will be delivered following NeoSync guidelines using the device user&#xD;
manual</description>
    <arm_group_label>active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham sTMS</intervention_name>
    <description>sham sTMS will be delivered following NeoSync guidelines using the device user manual</description>
    <arm_group_label>sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible male and female Veterans&#xD;
&#xD;
          -  between ages 18-70,&#xD;
&#xD;
          -  Veterans who currently meet criteria for SUD, and, if applicable, have stable&#xD;
             treatment regimen (i.e., medications and/or therapy) for at least 6 weeks prior to&#xD;
             study procedures&#xD;
&#xD;
          -  ongoing medications and psychotherapy will be allowed to continue unchanged during the&#xD;
             study&#xD;
&#xD;
          -  for safety, participants must also meet established criteria for MRI exposure, which&#xD;
             is implemented as a conservative measure given the novel application of sTMS in this&#xD;
             population&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy/lactation,&#xD;
&#xD;
          -  history of moderate or severe traumatic brain injury,&#xD;
&#xD;
          -  current or prior neurologic disorder or lifetime history of&#xD;
&#xD;
               -  seizure disorder&#xD;
&#xD;
               -  CNS tumors&#xD;
&#xD;
               -  stroke&#xD;
&#xD;
               -  cerebral aneurysm,&#xD;
&#xD;
          -  unstable medical condition,&#xD;
&#xD;
               -  active suicidality as assessed with the Columbia-Suicide Severity Rating Scale&#xD;
&#xD;
               -  primary psychotic disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E McGeary, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence VA Medical Center, Providence, RI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John E McGeary, PhD</last_name>
    <phone>(401) 273-7100</phone>
    <phone_ext>3393</phone_ext>
    <email>John.McGeary@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noah S Philip, MD</last_name>
    <phone>(401) 273-7100</phone>
    <phone_ext>6200</phone_ext>
    <email>noah.philip@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Providence VA Medical Center, Providence, RI</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John E McGeary, PhD</last_name>
      <phone>401-273-7100</phone>
      <phone_ext>3393</phone_ext>
      <email>John.McGeary@va.gov</email>
    </contact>
    <investigator>
      <last_name>John E McGeary, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

